Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd.
March 22, 2021
Share
On March 22, 2021, Noile-Immune Biotech Inc. closed the transaction. The company has amended the terms and received approximately ¥2,380,000,000 in the transaction. The transaction included participation from new investors Binex Holdings Co., Ltd., Shibuya Corporation (TSE:6340), The Dai-ichi Life Insurance Company, Limited, Healthcare Innovation Investment Limited Partnership, and KD Bio Investment Fund 4, and existing investor BiGEN Co., Ltd. The company has received ¥1,380,001,197 in its second tranche.
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd.